Charles River Laboratories (CRL) Tops Q4 EPS by 23c; Guides FY23 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Charles River Laboratories (CRL) shares plunge after Justice Department subpoena relating to NHPs
February 22, 2023 12:16 PM ESTCharles River Laboratories (NYSE: CRL) shares plummeted over 14% Wednesday after the company said in its latest earnings report that it has received a subpoena from the U.S. Department of Justice in connection with an investigation into the Cambodian non-human primate (NHP) supply... More



